科创板IPO进入冲刺阶段，核心医疗构筑从技术到商业的完整价值闭环

Core Insights - Shenzhen Core Medical Technology Co., Ltd. is pioneering the "next-generation artificial heart" in China's medical device innovation landscape, transitioning from "follow-up innovation" to "original innovation" [1] - The company is the only global entity with products approved for both implantable and interventional artificial hearts, marking a significant shift in the global artificial heart sector towards "Made in China" [1] Product Innovation - The first commercial product, Corheart 6, is the world's smallest and lightest full magnetic suspension implantable artificial heart, utilizing innovative technologies to enhance clinical value [2] - Corheart 6 employs "time-sharing dynamic axial full magnetic suspension control technology," significantly simplifying the structure of the magnetic suspension motor and overcoming traditional limitations in size and power consumption [2] Clinical Data and Validation - Long-term follow-up studies involving 50 patients across 12 clinical centers show a 2-year survival rate of 86% for Corheart 6, outperforming the HeartMate 3's 76.9% [3] - Corheart 6 is one of the few implantable artificial hearts in China to disclose long-term follow-up data based on registered clinical trials, reinforcing its safety and effectiveness [3] Market Position and Growth - Corheart 6 has quickly become the most implanted artificial heart in China, with over a thousand clinical applications, despite not being the first approved domestic product [4] - The global market for short-term artificial hearts is projected to grow from $2.07 billion in 2024 to $9.82 billion by 2033, with a compound annual growth rate (CAGR) of 18.9% [6] Strategic Expansion - Core Medical is expanding its product line to include interventional artificial hearts, with CorVad being the first domestically approved product in this category, targeting a previously untapped market [6] - The company is positioned to leverage its innovative technologies to create a comprehensive product portfolio that meets the full cycle of heart failure treatment needs [7] Global Outreach - Core Medical has established a clinical network across Asia, Europe, and America, achieving over 1,200 global implantations, setting a record for Chinese artificial heart companies in overseas approvals [9] - The company aims to enhance its research and development capabilities through its upcoming IPO, which seeks to raise up to 1.217 billion yuan for product development and industrialization projects [8]